Wolfe Research analyst Alex Zukin downgrades Salesforce (NYSE:CRM) from Outperform to Peer Perform.
Better Therapeutics And Glooko Announce Partnership To Accelerate Adoption Of AspyreRx To Treat Type 2 Diabetes In The U.S.
-Better Therapeutics Inc., a pioneer in developing prescription digital therapeutics (PDTs) for treating cardiometabolic diseases, and Glooko, Inc., a global leader in chronic condition management, today announced a